

# NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

## HIGHLY SPECIALISED TECHNOLOGY EVALUATION PROGRAMME

### Equality impact assessment – Guidance development

#### HST Givosiran for treating acute hepatic porphyria

The impact on equality has been assessed during this evaluation according to the principles of the NICE equality scheme.

#### Final evaluation determination

(when an ECD issued)

1. Have any additional potential equality issues been raised during the consultation, and, if so, how has the Committee addressed these?

No additional issues were raised.

2. If the recommendations have changed after consultation, are there any recommendations that make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

It was noted that acute hepatic porphyria is more common in women and that there is an increased risk of having an acute attack during or following pregnancy. The committee concluded that its recommendation applies equally, regardless of gender, so this difference is not in itself an equality issue.

3. If the recommendations have changed after consultation, is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No.

4. If the recommendations have changed after consultation, are there any recommendations or explanations that the Committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 2 and 3, or otherwise fulfil NICE's obligations to promote equality?

Not applicable.

5. Have the Committee's considerations of equality issues been described in the final evaluation determination, and, if so, where?

Yes, see section 4.35.

**Approved by Centre or Programme Director (name):** Jasdeep Hayre

**Date:** 05 October 2021